CliffBio
small molecule

WAINUA (AUTOINJECTOR)

EPLONTERSEN SODIUM

Loss of exclusivityAugust 2034latest FDA-listed patent expiry
CompanyASTRAZENECA AB

Drug detail

Brand nameWAINUA (AUTOINJECTOR)
Active ingredientEPLONTERSEN SODIUM
StrengthEQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalDecember 2023
Marketing statusRX

Listed patents

PatentExpiresType
10683499August 2034substance, product
9127276May 2034substance
9181549May 2034substance
8101743April 2026substance, product

Regulatory exclusivity

CodeExpires
ODE-461December 2030
NCEDecember 2028

More from ASTRAZENECA AB

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found